CoChat
Sign Up
Cited by 356

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

miRNA profiling of cancer

Di Leva, Gianpiero, Croce, Carlo M·2013·Current Opinion in Genetics & Development
DOI 10.1016/j.gde.2013.01.004PMC PMC3632255
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.gde.2013.01.004

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 63

  1. Bartel, 2004, Mirnas: genomics, biogenesis, mechanism, and function, Cell, 116, 281, 10.1016/S0092-8674(04)00045-5 · DOI
  2. Mendell, 2012, Mirnas in stress signaling and human disease, Cell, 148, 1172, 10.1016/j.cell.2012.02.005 · DOI · Paper page
  3. Kim, 2009, Biogenesis of small RNAs in animals, Nat Rev Mol Cell Biol, 10, 126, 10.1038/nrm2632 · DOI · Paper page
  4. Garofalo, 2011, miRNAs: master regulators as potential therapeutics in cancer, Annu Rev Pharmacol Toxicol, 51, 25, 10.1146/annurev-pharmtox-010510-100517 · DOI
  5. Calin, 2002, Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia, Proc Natl Acad Sci U S A, 99, 15524, 10.1073/pnas.242606799 · DOI · Paper page
  6. Esquela-Kerscher, 2006, Oncomirs—miRNAs with a role in cancer, Nat Rev Cancer, 6, 259, 10.1038/nrc1840 · DOI · Paper page
  7. Cimmino, 2005, miR-15 and miR-16 induce apoptosis by targeting BCL2, Proc Natl Acad Sci U S A, 102, 13944, 10.1073/pnas.0506654102 · DOI
  8. Klein, 2010, The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia, Cancer Cell, 17, 28, 10.1016/j.ccr.2009.11.019 · DOI
  9. Chen, 2008, Truncation of CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma, Blood, 112, 822, 10.1182/blood-2008-03-142182 · DOI
  10. Selcuklu, 2009, miR-21 as a key regulator of oncogenic processes, Biochem Soc Trans, 37, 918, 10.1042/BST0370918 · DOI
  11. Calin, 2005, A Mirna signature associated with prognosis and progression in chronic lymphocytic leukemia, N Engl J Med, 353, 1793, 10.1056/NEJMoa050995 · DOI
  12. Iorio, 2005, Mirna gene expression deregulation in human breast cancer, Cancer Res, 65, 7065, 10.1158/0008-5472.CAN-05-1783 · DOI · Paper page
  13. Yanaihara, 2006, Unique miRNA molecular profiles in lung cancer diagnosis and prognosis, Cancer Cell, 9, 189, 10.1016/j.ccr.2006.01.025 · DOI · Paper page
  14. He, 2005, The role of miRNA genes in papillary thyroid carcinoma, Proc Natl Acad Sci U S A, 102, 19075, 10.1073/pnas.0509603102 · DOI
  15. Roldo, 2006, Mirna expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior, J Clin Oncol, 24, 4677, 10.1200/JCO.2005.05.5194 · DOI
  16. Ciafrè, 2005, Extensive modulation of a set of miRNAs in primary glioblastoma, Biochem Biophys Res Commun, 334, 1351, 10.1016/j.bbrc.2005.07.030 · DOI · Paper page
  17. Chen, 2012, miRNA expression profile in primary gastric cancers and paired lymph node metastases indicates that miR-10a plays a role in metastasis from primary gastric cancer to lymph nodes, Exp Ther Med, 3, 351, 10.3892/etm.2011.411 · DOI
  18. Porkka, 2007, Mirna expression profiling in prostate cancer, Cancer Res, 67, 6130, 10.1158/0008-5472.CAN-07-0533 · DOI
  19. Murakami, 2006, Comprehensive analysis of miRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues, Oncogene, 25, 2537, 10.1038/sj.onc.1209283 · DOI
  20. Rosenfeld, 2008, Mirnas accurately identify cancer tissue origin, Nat Biotechnol, 26, 462, 10.1038/nbt1392 · DOI · Paper page
  21. Ferracin, 2011, Mirna profiling for the identification of cancers with unknown primary tissue-of-origin, J Pathol, 225, 43, 10.1002/path.2915 · DOI
  22. Volinia, 2006, A miRNA expression signature of human solid tumors defines cancer gene targets, Proc Natl Acad Sci U S A, 103, 2257, 10.1073/pnas.0510565103 · DOI · Paper page
  23. Lu, 2005, MicroRNA expression profiles classify human cancers, Nature, 435, 834, 10.1038/nature03702 · DOI
  24. Mattie, 2006, Optimized high-throughput miRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies, Mol Cancer, 5, 24, 10.1186/1476-4598-5-24 · DOI
  25. Blenkiron, 2007, Mirna expression profiling of human breast cancer identifies new markers of tumor subtype, Genome Biol, 8, R214, 10.1186/gb-2007-8-10-r214 · DOI
  26. Bockmeyer, 2011, Mirna profiles of healthy basal and luminal mammary epithelial cells are distinct and reflected in different breast cancer subtypes, Breast Cancer Res Treat, 130, 735, 10.1007/s10549-010-1303-3 · DOI
  27. Gregory, 2008, The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1, Nat Cell Biol, 10, 593, 10.1038/ncb1722 · DOI
  28. Howe, 2012, The miR-200 and miR-221/222 miRNA families: opposing effects on epithelial identity, J Mammary Gland Biol Neoplasia, 17, 65, 10.1007/s10911-012-9244-6 · DOI
  29. Radojicic, 2011, Mirna expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer, Cell Cycle, 10, 507, 10.4161/cc.10.3.14754 · DOI
  30. Shah, 2011, Mirnas miR-221 and miR-222: a new level of regulation in aggressive breast cancer, Genome Med, 3, 56, 10.1186/gm272 · DOI
  31. Stinson, 2011, TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer, Sci Signal, 4, ra41, 10.1126/scisignal.2001538 · DOI
  32. Volinia, 2012, Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of miRNA, Proc Natl Acad Sci U S A, 109, 3024, 10.1073/pnas.1200010109 · DOI
  33. Caramuta, 2010, Mirna expression profiles associated with mutational status and survival in malignant melanoma, J Invest Dermatol, 130, 2062, 10.1038/jid.2010.63 · DOI
  34. Garzon, 2008, Distinctive miRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin, Proc Natl Acad Sci U S A, 105, 3945, 10.1073/pnas.0800135105 · DOI
  35. Eis, 2008, Accumulation of miR-155 and BIC RNA in human B cell lymphomas, Proc Natl Acad Sci U S A, 102, 3627, 10.1073/pnas.0500613102 · DOI
  36. Kluiver, 2005, BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas, J Pathol, 207, 243, 10.1002/path.1825 · DOI
  37. Kluiver, 2006, Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma, Genes Chromosomes Cancer, 45, 147, 10.1002/gcc.20273 · DOI
  38. Costinean, 2006, Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice, Proc Natl Acad Sci U S A, 103, 7024, 10.1073/pnas.0602266103 · DOI
  39. Visone, 2009, Karyotype-specific miRNA signature in chronic lymphocytic leukemia, Blood, 114, 3872, 10.1182/blood-2009-06-229211 · DOI
  40. Chi, 2011, Mirna expression in multiple myeloma is associated with genetic subtype, isotype and survival, Biol Direct, 6, 23, 10.1186/1745-6150-6-23 · DOI
  41. Calin, 2004, Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers, Proc Natl Acad Sci U S A, 101, 2999, 10.1073/pnas.0307323101 · DOI
  42. Rao, 1998, Chromosomal and gene amplification in diffuse large B-cell lymphoma, Blood, 92, 234, 10.1182/blood.V92.1.234.413k22_234_240 · DOI
  43. De Leeuw, 2004, Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes, Hum Mol Genet, 13, 1827, 10.1093/hmg/ddh195 · DOI
  44. Neat, 2001, Localisation of a novel region of recurrent amplification in follicular lymphoma to an 6.8Mb region of 13q32–33, Genes Chromosomes Cancer, 32, 236, 10.1002/gcc.1187 · DOI
  45. Ota, 2004, Identification and characterization of a novel gene, C13orf25, as a target for 13q31–q32 amplification in malignant lymphoma, Cancer Res, 64, 3087, 10.1158/0008-5472.CAN-03-3773 · DOI
  46. He, 2005, A microRNA polycistron as a potential human oncogene, Nature, 435, 828, 10.1038/nature03552 · DOI
  47. Takamizawa, 2004, Reduced expression of the let-7 miRNAs in human lung cancers in association with shortened postoperative survival, Cancer Res, 64, 3753, 10.1158/0008-5472.CAN-04-0637 · DOI
  48. Ji, 2009, Mirna expression, survival, and response to interferon in liver cancer, N Engl J Med, 361, 1437, 10.1056/NEJMoa0901282 · DOI
  49. Li, 2010, Survival prediction of gastric cancer by a seven-miRNA signature, Gut, 59, 579, 10.1136/gut.2008.175497 · DOI
  50. Rossi, 2010, miRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival, Blood, 116, 945, 10.1182/blood-2010-01-263889 · DOI
  51. Dillhoff, 2008, Mirna-21 is overexpressed in pancreatic cancer and a potential predictor of survival, J Gastrointest Surg, 12, 2171, 10.1007/s11605-008-0584-x · DOI
  52. Schetter, 2008, Mirna expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma, JAMA, 299, 425, 10.1001/jama.299.4.425 · DOI
  53. Ali, 2010, Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF, Cancer Res, 70, 3606, 10.1158/0008-5472.CAN-09-4598 · DOI
  54. Giannini, 2012, Effectiveness of α-fetoprotein for hepatocellular carcinoma surveillance: the return of the living-dead?, Expert Rev Gastroenterol Hepatol, 6, 441, 10.1586/egh.12.30 · DOI
  55. Balk, 2003, Biology of prostate-specific antigen, J Clin Oncol, 21, 383, 10.1200/JCO.2003.02.083 · DOI
  56. Duffy, 2006, Serum tumor markers in breast cancer: are they of clinical value?, Clin Chem, 52, 345, 10.1373/clinchem.2005.059832 · DOI
  57. Díaz-Padilla, 2012, Prognostic and predictive value of CA-125 in the primary treatment of epithelial ovarian cancer: potentials and pitfalls, Clin Transl Oncol, 14, 15, 10.1007/s12094-012-0756-8 · DOI
  58. Lawrie, 2008, Detection of elevated levels of tumour-associated miRNAs in serum of patients with diffuse large B-cell lymphoma, Br J Haematol, 141, 672, 10.1111/j.1365-2141.2008.07077.x · DOI
  59. Mitchell, 2008, Circulating miRNAs as stable blood-based markers for cancer detection, Proc Natl Acad Sci U S A, 105, 10513, 10.1073/pnas.0804549105 · DOI · Paper page
  60. Chen, 2012, Could circulating microRNAs contribute to cancer therapy?, Trends Mol Med
  61. Heneghan, 2010, Circulating miRNAs as novel minimally invasive biomarkers for breast cancer, Ann Surg, 251, 499, 10.1097/SLA.0b013e3181cc939f · DOI
  62. Zhu, 2009, Circulating miRNAs in breast cancer and healthy subjects, BMC Res Notes, 2, 89, 10.1186/1756-0500-2-89 · DOI
  63. Fabbri, 2012, Mirnas bind to Toll-like receptors to induce prometastatic inflammatory response, Proc Natl Acad Sci U S A, 109, E2110, 10.1073/pnas.1209414109 · DOI · Paper page

Cited by

Sorted by citations

See all 356

Metadata

Authors
Di Leva, G., & Croce, C. M.
Venue
Current Opinion in Genetics & Development
Publisher
Elsevier BV
Published
2013-02
Volume
23
Issue
1
Pages
3-11
ISSN
0959-437X
DOI
10.1016/j.gde.2013.01.004
PMC
PMC3632255
Cited by
356
References
4
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: miRNA profiling of cancer. https://app.cochat.ai/papers/10.1016/j.gde.2013.01.004
The paper
Di Leva, G., & Croce, C. M. (2013). miRNA profiling of cancer. Current Opinion in Genetics & Development. https://doi.org/10.1016/j.gde.2013.01.004